BACKGROUND: Pediatric brainstem tumors (BST) comprise a heterogeneous group of entities. Data regarding treatment options and outcome of BST, specifically brainstem low grade tumors (BSLGT) are limited. In order to better define risk groups and evaluate treatment options for pediatric BST, we performed a comprehensive analysis of all BST patients treated in our hospital during the MRI era. PROCEDURES: We retrospectively analyzed clinical, imaging, and pathology data at presentation, treatment, and outcome of all BST patients followed at the Hospital for Sick Children in Toronto over the last 25 years. RESULTS: Of 1,801 children with brain tumors, 223 (12%) had a brainstem primary location. Tumors without pontine involvement were BSLGT in 98.3%, whereas 75% of tumors involving the pons were high grade (P = 0.0001). Patients with BSLGT had 5-year progression-free survival (PFS) and overall survival (OS) of 57 ± 3% and 89 ± 5%, respectively. Upfront observation of tumor residual conferred no survival disadvantage with 5-year PFS and OS of 57 ± 5% and 93 ± 3%, respectively. In the group of patients requiring further treatment, 5-year PFS and OS were comparable between chemotherapy and radiotherapy with 53 ± 12% and 93 ± 4% and 66 ± 11% and 83 ± 6%, respectively (P = 0.26 and 0.3, respectively). CONCLUSION: BST without pontine involvement are almost invariably BSLGT. Children with BSLGT have an excellent outcome even with careful initial observation. No clear benefit was observed for radiotherapy over chemotherapy when adjuvant treatment was needed. A conservative approach may be warranted for children with non-pontine brainstem lesions.
BACKGROUND:Pediatric brainstem tumors (BST) comprise a heterogeneous group of entities. Data regarding treatment options and outcome of BST, specifically brainstem low grade tumors (BSLGT) are limited. In order to better define risk groups and evaluate treatment options for pediatric BST, we performed a comprehensive analysis of all BST patients treated in our hospital during the MRI era. PROCEDURES: We retrospectively analyzed clinical, imaging, and pathology data at presentation, treatment, and outcome of all BST patients followed at the Hospital for Sick Children in Toronto over the last 25 years. RESULTS: Of 1,801 children with brain tumors, 223 (12%) had a brainstem primary location. Tumors without pontine involvement were BSLGT in 98.3%, whereas 75% of tumors involving the pons were high grade (P = 0.0001). Patients with BSLGT had 5-year progression-free survival (PFS) and overall survival (OS) of 57 ± 3% and 89 ± 5%, respectively. Upfront observation of tumor residual conferred no survival disadvantage with 5-year PFS and OS of 57 ± 5% and 93 ± 3%, respectively. In the group of patients requiring further treatment, 5-year PFS and OS were comparable between chemotherapy and radiotherapy with 53 ± 12% and 93 ± 4% and 66 ± 11% and 83 ± 6%, respectively (P = 0.26 and 0.3, respectively). CONCLUSION: BST without pontine involvement are almost invariably BSLGT. Children with BSLGT have an excellent outcome even with careful initial observation. No clear benefit was observed for radiotherapy over chemotherapy when adjuvant treatment was needed. A conservative approach may be warranted for children with non-pontine brainstem lesions.
Authors: Matthew Mistry; Nataliya Zhukova; Daniele Merico; Patricia Rakopoulos; Rahul Krishnatry; Mary Shago; James Stavropoulos; Noa Alon; Jason D Pole; Peter N Ray; Vilma Navickiene; Joshua Mangerel; Marc Remke; Pawel Buczkowicz; Vijay Ramaswamy; Ana Guerreiro Stucklin; Martin Li; Edwin J Young; Cindy Zhang; Pedro Castelo-Branco; Doua Bakry; Suzanne Laughlin; Adam Shlien; Jennifer Chan; Keith L Ligon; James T Rutka; Peter B Dirks; Michael D Taylor; Mark Greenberg; David Malkin; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Uri Tabori Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Santhosh A Upadhyaya; Carl Koschmann; Karin Muraszko; Sriram Venneti; Hugh J Garton; Daniel A Hamstra; Cormac O Maher; Bryan L Betz; Noah A Brown; Daniel Wahl; Helmut C Weigelin; Kathleen E DuRoss; Annette S Leonard; Patricia L Robertson Journal: J Child Neurol Date: 2016-11-03 Impact factor: 1.987
Authors: Margot A Lazow; Christine Fuller; Mariko DeWire; Adam Lane; Pratiti Bandopadhayay; Ute Bartels; Eric Bouffet; Sylvia Cheng; Kenneth J Cohen; Tabitha M Cooney; Scott L Coven; Hetal Dholaria; Blanca Diez; Kathleen Dorris; Moatasem El-Ayadi; Ayman El-Sheikh; Paul G Fisher; Adriana Fonseca; Mercedes Garcia Lombardi; Robert J Greiner; Stewart Goldman; Nicholas Gottardo; Sridharan Gururangan; Jordan R Hansford; Tim Hassall; Cynthia Hawkins; Lindsay Kilburn; Carl Koschmann; Sarah E Leary; Jie Ma; Jane E Minturn; Michelle Monje-Deisseroth; Roger Packer; Yvan Samson; Eric S Sandler; Gustavo Sevlever; Christopher L Tinkle; Karen Tsui; Lars M Wagner; Mohamed Zaghloul; David S Ziegler; Brooklyn Chaney; Katie Black; Anthony Asher; Rachid Drissi; Maryam Fouladi; Blaise V Jones; James L Leach Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: Paul Klimo; Atmaram S Pai Panandiker; Clinton J Thompson; Frederick A Boop; Ibrahim Qaddoumi; Amar Gajjar; Gregory T Armstrong; David W Ellison; Larry E Kun; Robert J Ogg; Robert A Sanford Journal: J Neurosurg Pediatr Date: 2013-01-04 Impact factor: 2.375
Authors: Roger J Packer; Stephan Pfister; Eric Bouffet; Robert Avery; Pratiti Bandopadhayay; Miriam Bornhorst; Daniel C Bowers; David Ellison; Jason Fangusaro; Nicholas Foreman; Maryam Fouladi; Amar Gajjar; Daphne Haas-Kogan; Cynthia Hawkins; Cheng-Ying Ho; Eugene Hwang; Nada Jabado; Lindsay B Kilburn; Alvaro Lassaletta; Keith L Ligon; Maura Massimino; Schouten-van Meeteren; Sabine Mueller; Theo Nicolaides; Giorgio Perilongo; Uri Tabori; Gilbert Vezina; Katherine Warren; Olaf Witt; Yuan Zhu; David T Jones; Mark Kieran Journal: Neuro Oncol Date: 2017-06-01 Impact factor: 12.300